Skip to content

Adjuvance Technologies

Empowering health.

Our Technology
Our Leadership
- Management Team
- Board of Directors
Investors & Media
Contact

Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer

By jgardnerMay 20, 2013Publications

Natural and synthetic saponin adjuvant QS-21 for vaccines against cancer

Adjuvance’s co-founding scientists review the application of natural and synthetic QS-21 in cancer vaccinology.

Post navigation

KEY PATENT AWARDED TO ADJUVANCE CO-FOUNDERS FOR PIONEERING METHOD OF PRODUCING RARE VACCINE COMPONENT.

Nature Chemistry: Development of a minimal saponin vaccine adjuvant based on QS-21

Recent Posts

Comparative preclinical evaluation of AS01 versus other Adjuvant systems in a candidate herpes zoster glycoprotein E subunit vaccine
NEJM Reports Efficacy of QS-21 Containing Herpes Zoster Subunit Vaccine
Vaccine Adjuvant Systems containing monophosphoryl lipid A andQS-21 induce strong humoral and cellular immune responses against hepatitis B surface antigen which persist for at least 4 years after vaccination
Design, synthesis, and immunologic evaluation of vaccine adjuvant conjugates based on QS-21 and tucaresol
Nature Chemistry: Development of a minimal saponin vaccine adjuvant based on QS-21

Copyright © All rights reserved. Theme Businessbiz by Sensational Theme